The deal is aimed at expanding the clinical trial site network of Eximia. Credit: Michal Jarmoluk from Pixabay.

Eximia Research Network has announced the acquisition of Tidewater Clinical Research, marking a significant expansion of its national clinical trial site network.

Established in 1994, Tidewater Clinical Research focuses on Women’s Health and Ophthalmology clinical trials in the Hampton Roads/Eastern Virginia region in the US.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The integration of Tidewater’s capabilities and patient database with Eximia’s extensive resources is expected to enhance clinical trial experiences.

Tidewater owner Kelley Fleming said: “Tidewater Clinical Research is proud to announce our integration into the Eximia Research Network, marking a significant step forward in enhancing clinical research accessibility and quality of care for diverse patient populations.”

Tidewater co-owner April Rusch said: “Under the Eximia umbrella, Tidewater is poised to broaden its impact on patient health and contribute to the advancement of medical research in ever-expanding medical subspecialty areas.”

For the transaction, David Bogart and Devak Patel from Viking Mergers & Acquisitions served as advisers.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Viking Mergers & Acquisitions, which has been in operation since 1996, is a business broker in the Southeast US. It has a track record of having sold over 850 businesses.

Eximia Research Network CEO Dr Ella Grach said: “We are excited to welcome Tidewater Clinical Research to the Eximia network.

“Their expertise in Women’s Health and Ophthalmology complements our mission to drive innovation and improve patient outcomes. This acquisition enhances our ability to serve diverse populations and support groundbreaking clinical research nationwide.”

In October last year, Eximia secured a growth capital investment from private investment company VSS Capital Partners (VSS).

The companies did not disclose the financial terms of the deal.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact